Lotus Pharmaceutical   Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Taipei Taiwan (1966)
Status: Acquired by Alvogen (2014)

Organization Overview

First Clinical Trial
2004
NCT00334178
First Marketed Drug
2010
levetiracetam (keppra)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LOTUS PHARM CO LTD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Migraine Disorders (Phase 3)

Migraine with Aura (Phase 3)

Migraine without Aura (Phase 3)

Urticaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5